<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146275">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01881386</url>
  </required_header>
  <id_info>
    <org_study_id>13/LO/0536 CCR3939</org_study_id>
    <nct_id>NCT01881386</nct_id>
  </id_info>
  <brief_title>Lactate Imaging as a Tumour Biomarker</brief_title>
  <official_title>Investigation of Lactate Measured Using Magnetic Resonance Spectroscopy as a Biomarker of Tumour Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is designed to investigate whether measurements of lactate in tumours, made
      using a magnetic resonance technique similar to MRI, is an effective non-invasive method to
      detect whether some new targeted drugs are having their desired effect.

      The study hypothesis is that by using magnetic resonance spectroscopy techniques, we will be
      able to observe changes in tumour lactate levels in vivo, in response to treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Correlation between changes in MRS lactate measurements at two time points after treatment and clinical response</measure>
    <time_frame>7 and 21 days post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of MRS lactate measurement</measure>
    <time_frame>Two baseline measurements taken at day -7 to 0 pre-treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between changes in post treatment MRS lactate measurements and serum lactate dehydrogenase</measure>
    <time_frame>Baseline and 7 and 21 days post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Lymphoma</arm_group_label>
    <description>Lymphoma patients before and after receiving standard CHOP therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Colorectal</arm_group_label>
    <description>Patients with metastatic colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <description>Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>Magnetic Resonance Spectroscopy</description>
    <arm_group_label>Lymphoma</arm_group_label>
    <arm_group_label>Metastatic Colorectal</arm_group_label>
    <arm_group_label>Phase 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort 1:lymphoma patients

          -  minimum lesion size of 2cm

          -  not pre-treated but scheduled to be treated with CHOP (Cyclophosphamide,
             Hydroxydaunomycin,Oncovin and Prednisilone)

        Cohort 2:Colorectal patients

          -  metastatic disease of at least 2cm

          -  not pre-treated

        Cohort 3:Phase 1 Drug Development

          -  minimum lesion size at least 2cm

        Exclusion Criteria:

          -  MRI incompatible metal implants

          -  Claustrophobia

          -  Inability to tolerate a 40 minute MRI scan
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nandita deSouza, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nandita deSouza, Professor</last_name>
    <phone>0208 661 3289</phone>
    <email>nandita.desouza@icr.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine May, BSc</last_name>
    <phone>0208 642 6011</phone>
    <phone_ext>4109</phone_ext>
    <email>katherine.may@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Institute of Cancer Research and Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nandita deSouza, Professor</last_name>
      <phone>0208 661 3289</phone>
      <email>nandita.desouza@icr.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Katherine May, BSc</last_name>
      <phone>0208 661 3340</phone>
      <email>katherine.may@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Geoffrey Payne, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 3, 2013</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Cancer Research, United Kingdom</investigator_affiliation>
    <investigator_full_name>NdeSouza</investigator_full_name>
    <investigator_title>Professor of Translational Imaging</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Spectroscopy</keyword>
  <keyword>Lactate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
